ICOS Is an Indicator of T-cell–Mediated Response to Cancer Immunotherapy

Abstract

Statement of significance ICOS ImmunoPET is a promising strategy to noninvasively predict and monitor immunotherapy response. Research.

ICOS+ Tregs: A Functional Subset of Tregs in Immune Diseases

“…The CAR with the ICOS-4-1BB fusing protein increased CAR-T cell persistence in vivo and anti-tumor efficacy ( 147 ). Additionally, a technology using a 89 Zr-DFO-ICOS mAb as a probe for PET imaging was developed as a non-invasive strategy to monitor or allow for the early prediction of therapeutic responses by quantifying the number of ICOS + activated T cells in a Lewis lung cancer model ( 148 ). In other words, there is great potentiality for the use of ICOS as a therapeutic target in the treatment of tumors.…”

Correlations of the expression of γδ T cells and their co-stimulatory molecules TIGIT, PD-1, ICOS and BTLA with PR and PIBF in the peripheral blood and decidual tissues of women with unexplained recurrent spontaneous abortion

“…TIGIT, BTLA and PD-1 are T cell surface receptors and negative co-stimulatory molecules, which can inhibit T cell activation and proliferation by binding to corresponding ligands [16][17][18]. ICOS is an inducible costimulatory molecule that can promote the proliferation and activation of T cells [19]. However, the expression of these molecules on γδ T cells in the peripheral blood and decidual tissues of women with URSA has not been reported.…”

Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET

“…In an effort to identify surface activation markers as candidate targets for immunoPET, we analyzed recently published RNA sequencing data obtained from human CD4 + and CD8 + CD19.28z CAR T cells cultured in vitro (32). The analysis was restricted to a selected list of markers known to be upregulated during activation on the T cell surface and previously employed as targets for PET imaging (27,29,40,41). As shown in Figure 1A, transcripts of most of the selected markers were expressed at high levels early after activation (day 7) and decreased at later time points (day 10 and day 14).…”

“…Advantageously, the radiolabeled antibodies can be injected at different time points post administration of the cells and even repeatedly to allow longitudinal and serial assessment of CAR T cell persistence. Target molecules evaluated to date to study T cell immune responses principally include lineage defining molecules such as CD3 (20,21), CD4 (22,23), CD7 (24) and/or CD8 (25,26) and T-cell surface activation markers such as OX40 (27), HLA-DR (28) and ICOS (29). Our group and others have evaluated such approaches for monitoring different classes of cancer immunotherapies in preclinical models, including tumor vaccination (27,29), immune checkpoint blockade (29) and allogeneic hematopoietic stem cell transplantation (28,30).…”